Truist downgraded Treace Medical to Hold from Buy with a price target of $7, down from $17, on a reduced growth outlook and projected deceleration trend in Q2. Treace is facing increasing competitive dynamics that the firm fears are “potentially structural in nature” and could make it hard for the growth trajectory and stock to sustainably rebound, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI: